



August 27, 2021

RBC Capital Markets U.S. Small Cap Growth Idea List

August Update

RBC Capital Markets US Research is updating its Small Cap Growth Idea list. This is a quarterly list of our highest conviction Small Cap Growth recommendations. The list is an opportunity to highlight companies that have either an attractive normalized growth story or strong durable growth characteristics. We feature companies with market capitalizations below \$5 billion (as of joining the list), and a minimum average daily trading value of \$10 million.

Our updated list includes four software names: **JAMF Holdings**, **Rapid7**, and new additions in **PING Identity Holding** who is well suited to manage and secure identities of some of the largest and most complex hybrid-cloud global organizations with the potential to re-accelerate ARR as the environment normalizes, as well as **PubMatic**, who is well positioned to benefit from an accelerated shift towards digital advertising post-pandemic, with Supply Path Optimization (SPO) as a company specific catalyst. We add internet exposure to the list with recent upgrade, **CarGurus**, as their CarOffer business demonstrates momentum and better positions the company to take advantage of secular online car retailing trends. Rounding out technology, we add **Flywire** to the list following its May IPO, a company we believe is uniquely positioned to solve various payment friction points embedded in its key verticals, which include education, healthcare, and travel. In healthcare technology, **OptimizeRx** and **Tabula Rasa HealthCare** remain high conviction ideas, as do biopharma names **Global Blood Therapeutics**, **Intra-Cellular Therapies**, and **Sarepta Therapeutics**. We add **Arena Pharmaceuticals** to the list given ulcerative colitis treatment etrasimod's potentially best-in-class clinical-stage profile. In energy, we reiterate high conviction in **Matador Resources** and add to the list recent initiation **Sunnova Energy International**, a leader in the growing US residential rooftop solar market with ~4-5% share based on our estimates, but is capturing a larger portion of the market's growth. In financials, we reiterate high conviction in **Goosehead Insurance** and **Kinsale Capital Group**. Please see the body of this note for additional details on each name's investment thesis and as always, we encourage you to reach out to the team with any questions.

Additions (6): Arena Pharmaceuticals, Inc., CarGurus, Inc., Flywire Corporation, Ping Identity Holding Corp., Pubmatic, Inc., Sunnova Energy International Inc

Deletions (6): Dicerna Pharmaceuticals, Inc., Olo Inc., Pacira Biosciences, Inc., Rackspace Technology Inc., SailPoint Technologies Holdings, Inc., SelectQuote Inc.

Exhibit 1 - RBC Capital Markets Small Cap Growth Idea List

Company	Pricing Symbol	Analyst	Rating	Trading Currency	Closing Price (08/26/2021)	Market Cap (MM)	Price Target	Dividend Yield (%)	Implied All-in Return (%)
Intra-Cellular Therapies, Inc.	ITCI US	Brian Abrahams	Outperform	USD	31.11	2,766	45.00	0.00	44.7
Sarepta Therapeutics, Inc.	SRPT US	Brian Abrahams	Outperform	USD	78.33	6,110	148.00	0.00	88.9
OptimizeRx Corporation	OPRX US	Sean Dodge	Outperform	USD	64.77	1,172	67.00	0.00	3.4
Tabula Rasa HealthCare, Inc.	TRHC US	Sean Dodge	Outperform	USD	31.26	728	70.00	0.00	123.9
Goosehead Insurance Inc	GSHD US	Mark Dwelle	Outperform	USD	129.55	4,703	155.00	0.00	19.6
Kinsale Capital Group, Inc.	KNSL US	Mark Dwelle	Outperform	USD	175.49	4,054	235.00	0.25	34.2
CarGurus, Inc.	CARG US	Brad Erickson	Outperform	USD	29.42	3,514	40.00	0.00	36.0
Matador Resources Company	MTDR US	Scott Hanold	Outperform	USD	27.08	3,162	40.00	0.37	48.1
Jamf Holding Corp.	JAMF US	Matthew Hedberg	Outperform	USD	34.09	4,173	45.00	0.00	32.0
Rapid7, Inc.	RPD US	Matthew Hedberg	Outperform	USD	116.25	7,184	138.00	0.00	18.7
Ping Identity Holding Corp.	PING US	Matthew Hedberg	Outperform	USD	25.66	2,091	38.00	0.00	48.1
Arena Pharmaceuticals, Inc.	ARNA US	Kennen MacKay	Outperform	USD	50.76	2,030	76.00	0.00	49.7
Flywire Corporation	FLYW US	Daniel R. Perlin	Outperform	USD	38.56	4,485	47.00	0.00	21.9
Global Blood Therapeutics, Inc.	GBT US	Gregory Renza	Outperform	USD	28.28	1,762	66.00	0.00	133.4
Sunnova Energy International Inc	NOVA US	Elvira Scotto	Outperform	USD	34.79	3,896	59.00	0.00	69.6
Pubmatic, Inc.	PUBM US	Matthew Swanson	Outperform	USD	27.05	1,526	47.00	0.00	73.8

Source: RBC Capital Markets estimates, Bloomberg

Priced as of market close on August 26, 2021, unless otherwise indicated.
All values in USD unless otherwise noted.

Table of Contents

Investment Summaries – Technology	4
CarGurus, Inc. (NASDAQ: CARG)	5
Flywire Corporation (NASDAQ: FLYW)	6
Jamf Holding Corp. (NASDAQ: JAMF)	7
Ping Identity Holding Corp. (NYSE: PING)	8
Pubmatic, Inc. (NASDAQ: PUBM)	9
Rapid7 Inc. (NASDAQ: RPD)	10
Investment Summaries – Biopharma	11
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA)	12
Global Blood Therapeutics, Inc. (NASDAQ: GBT)	13
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)	14
Sarepta Therapeutics, Inc. (NASDAQ: SRPT)	15
Investment Summaries – Healthcare Technology	16
OptimizeRx Corp (NASDAQ: OPRX)	17
Tabula Rasa HealthCare Inc. (NASDAQ: TRHC)	18
Investment Summaries – Energy	19
Matador Resources Company (NYSE: MTDR)	20
Sunnova Energy International Inc. (NYSE: NOVA)	21
Investment Summaries – Financials	22
Goosehead Insurance Inc. (NASDAQ: GSHD)	23
Kinsale Capital Group Inc (NASDAQ: KNSL)	24
Contributing Authors	25
Required disclosures	26

Changes to the list

Recurring names

Company	Pricing Symbol	Analyst	Rating	Trading Currency	Closing Price 08/26/2021	Price Target	Added to the List
Global Blood Therapeutics, Inc.	GBT US	Gregory Renza	Outperform	USD	28.28	66.00	02/03/2021
Goosehead Insurance Inc	GSHD US	Mark Dwelle	Outperform	USD	129.55	155.00	02/03/2021
Intra-Cellular Therapies, Inc.	ITCI US	Brian Abrahams	Outperform	USD	31.11	45.00	04/27/2021
Jamf Holding Corp.	JAMF US	Matthew Hedberg	Outperform	USD	34.09	45.00	10/13/2021
Kinsale Capital Group, Inc.	KNSL US	Mark Dwelle	Outperform	USD	175.49	235.00	04/27/2021
Matador Resources Company	MTDR US	Scott Hanold	Outperform	USD	27.08	40.00	04/27/2021
OptimizeRx Corporation	OPRX US	Sean Dodge	Outperform	USD	64.77	67.00	04/27/2021
Rapid7, Inc.	RPD US	Matthew Hedberg	Outperform	USD	116.25	138.00	02/03/2021
Sarepta Therapeutics, Inc.	SRPT US	Brian Abrahams	Outperform	USD	78.33	148.00	04/27/2021
Tabula Rasa HealthCare, Inc.	TRHC US	Sean Dodge	Outperform	USD	31.26	70.00	07/08/2021

Source: RBC Capital Markets estimates, Bloomberg

Additions to the U.S. Small Cap Growth Idea List

Company	Pricing Symbol	Analyst	Rating	Trading Currency	Closing Price 08/26/2021	Price Target	Added to the List
Arena Pharmaceuticals, Inc.	ARNA US	Kennen MacKay	Outperform	USD	50.76	76.00	08/27/2021
CarGurus, Inc.	CARG US	Brad Erickson	Outperform	USD	29.42	40.00	08/27/2021
Flywire Corporation	FLYW US	Daniel R. Perlin	Outperform	USD	38.56	47.00	08/27/2021
Ping Identity Holding Corp.	PING US	Matthew Hedberg	Outperform	USD	25.66	38.00	08/27/2021
Pubmatic, Inc.	PUBM US	Matthew Swanson	Outperform	USD	27.05	47.00	08/27/2021
Sunnova Energy International Inc	NOVA US	Elvira Scotto	Outperform	USD	34.79	59.00	08/27/2021

Source: RBC Capital Markets estimates, Bloomberg

Deletions from the U.S. Small Cap Growth Idea List

Company	Pricing Symbol	Analyst	Rating	Trading Currency	Closing Price 08/26/2021	Price Target	Added to the list	Removed from the list
Dicerna Pharmaceuticals, Inc.	DRNA US	Luca Issi	Outperform *	USD	20.11	30.00	02/03/2021	08/27/2021
Olo Inc.	OLO US	Matthew Hedberg	Outperform	USD	46.56	40.00	04/27/2021	08/27/2021
Pacira Biosciences, Inc.	PCRX US	Gregory Renza	Outperform	USD	57.48	86.00	04/08/2020	08/27/2021
Rackspace Technology Inc	RXT US	Daniel R. Perlin	Outperform	USD	13.52	24.00	10/13/2020	08/27/2021
SailPoint Technologies Holdings, Inc.	SAIL US	Matthew Hedberg	Outperform	USD	46.56	60.00	04/08/2020	08/27/2021
SelectQuote Inc	SLQT US	Frank Morgan	Sector Perform	USD	7.89	13.00	02/03/2021	08/27/2021

Note: *Denotes Speculative Risk

Source: RBC Capital Markets estimates, Bloomberg

Investment Summaries – Technology

CarGurus, Inc. (NASDAQ: CARG)

Brad Erickson (Analyst)
(503) 830-9488
brad.erickson@rbccm.com

Rating: Outperform

Closing Price: \$29.42

Price Target: \$40.00

Implied All-in Return: 36.0%

Most recent company note: [link](#)

Investment summary

CARG is the largest car shopping site in the U.S. by traffic and leverages a differentiated, freemium-based approach to offer the most inventory of any shopping site. We are bullish on the stock on the back of bringing together CarOffer's two-sided marketplace technology and CarGuru's industry-leading audience to move down the funnel and extract greater economics from retail and wholesale car sales in the U.S.

Valuation

The stock trades at 2.9x EV/'22E revenue and 12.9x EV/'22E EBITDA, both discounts relative to the peer group. That said, early success with the recently acquired CarOffer business coupled with its Max Cash Offer platform shows a promising downfunnel opportunity, which we believe can drive the next leg of growth for CARG, provide synergies to the core lead-gen business, and direct multiple expansion. To that end, we use an 18.6x EV/'22E EBITDA multiple to derive our \$40 price target, which supports our Outperform rating.

Risks to rating and price target

Pandemic relapses causing disruption to the used car market, such as lack of liquidity in asset-backed markets and/or inventory constraints; new car supply constraints leading to lower used car inventory; lack of traction within the wholesale market; lower industry gross profits/vehicle leading to lower advertising spend/vehicle; rising interest rates, inflation, and/or a macroeconomic downturn.

Flywire Corporation (NASDAQ: FLYW)

Daniel Perlin (Analyst)
(410) 625-6130
daniel.perlin@rbccm.com

Rating: Outperform

Closing Price: \$38.56

Price Target: \$47.00

Implied All-in Return: 21.9%

Most recent company note: [link](#)

Investment summary

We believe Flywire is uniquely positioned to solve various payment friction points embedded in its key verticals, which include education, healthcare, and travel. Growth in the company's end markets, high retention rates, market share gains, new products and expansion into additional verticals should support 30%+ revenue CAGR over the next three years. While the company is currently investing in the business to support this revenue growth, we believe it will turn adjusted EBITDA positive in FY23 and long-term adjusted EBITDA margins could approach 25%+ with the revenue CAGR remaining ~30%. **We believe FLYW's success will be underpinned by several attributes**, which in our opinion include 1) its focus on large and unique addressable markets, 2) Flywire Advantage, its technology platform, setting itself apart from the peers resulting in high retention rates and new client wins, 3) the competitive moat provided by FLYW's proprietary global payment network (over a decade to build) and vertical-specific software, and 4) the potential call option the company has as it expands into B2B payments.

Valuation

Our price target of \$47 is based on an EV/revenue multiple of 25x our CY22 revenue estimate of \$202M. This target is in line with the company's peers and reflective of the company's anticipated 30%+ long-term revenue growth CAGR and achieving consistent EBITDA profitability in FY23. The implied upside supports our Outperform rating.

Risks to rating and price target

We believe there are three broad risk categories: (1) macro-economic risks; (2) regulatory & compliance risks; and (3) competitive risks including pricing and technological changes. In terms of specific risks, we note that since inception, Flywire has incurred net losses from operations and despite significant revenue growth in recent periods, it is uncertain whether the company will obtain high enough volumes to sustain / increase growth or achieve / maintain profitability in the future. The company's key verticals, furthermore, are highly competitive and regulated while evolving rapidly. Finally, a group of major shareholders control a significant portion of FLYW's voting and economic rights.

Jamf Holding Corp. (NASDAQ: JAMF)

Matthew Hedberg (Analyst)

(612) 313-1293

matthew.hedberg@rbccm.com

Rating: Outperform

Closing Price: \$34.09

Price Target: \$45.00

Implied All-in Return: 32.0%

Most recent company note: [link](#)

Investment summary

We see Jamf's primary mission as being to help organizations succeed with Apple. As the standard in Apple enterprise management, we think Jamf is in a strong position to leverage the growing preference for Apple in the enterprise. In addition to a TAM that is likely to expand more quickly than previously expected in a post-COVID world, the company's financial profile is unique given rapid growth and high profitability. **Apple innovation has transformed the technology landscape.** What started off as a consumer revolution to Apple devices has steadily made its way to the enterprise. As such, there has been a substantial share shift in operating system usage since 2009, with iOS representing 32% of Internet traffic in the US and macOS 12%, for a total of 43%, which is significantly higher than Windows at 31%. To put that into perspective, in 2009 Windows-based devices drove 88% of Internet traffic vs. iOS at 1% and macOS at 10%. Jamf currently manages over 17 million Apple Devices for over 40,000 customers in over 100 countries. **Expanding the TAM.** The company has provided a bottom-up estimate of \$10.3 billion TAM in 2019, growing at a CAGR of 17.8% to \$23.4 billion by 2024.

Valuation

Our \$45 price target is based on shares trading at 14.9x CY/21E EV/S and 12.1x CY/22E EV/S. This is a slight premium to similar growing SaaS peers on both CY/21E and CY/22E, which we think is warranted due to a unique investment opportunity, potential conservatism to our published estimates, and ESG characteristics. Revenue growth for Jamf in 2019 was 39%. If ARR growth in 2021 were to stay at +30% in-line with our current estimate, one could argue for additional multiple expansion based on peers. Our price target supports an Outperform rating.

Risks to rating and price target

(1) The impact on Jamf's operations and financial condition from COVID-19. (2) Changes in Jamf's continued relationship with Apple including the adverse impact of changes in features and functionality by Apple on Jamf's engineering focus or product development efforts. (3) Jamf derives a substantial portion of its revenue from one product; as of CY/19, sales of Jamf Pro accounted for ~78% of total revenue.

Ping Identity Holding Corp. (NYSE: PING)

Matthew Hedberg (Analyst)

(612) 313-1293

matthew.hedberg@rbccm.com

Rating: Outperform

Closing Price: \$25.66

Price Target: \$38.00

Implied All-in Return: 48.1%

Most recent company note: [link](#)

Investment summary

Ping has extensive history as a pioneer and thought leader within the Identity industry. From its beginning with single sign-on (SSO) to the addition of multi-factor authentication (MFA) to API security and more, we believe Ping is well suited to manage and secure identities of some of the largest and most complex hybrid-cloud global organizations. Enterprises are undergoing digital transformations while concurrently becoming more distributed, which dissolves the traditional network perimeter. As a result, we believe enterprises require Intelligent Identity solutions that proactively ensure the right user has authorized access to resources at the appropriate time.

Valuation

We calculate our base-case price target of \$38 by applying a 9.0x EV/ARR multiple to our CY/22E ARR estimate of \$352M. This multiple is a slight discount to 10-20% growing peers. Additionally, our target is 10.4x EV/S on our CY/22E revenue estimate of \$304M, as revenue is suppressed due to the mix-shift toward SaaS. Our price target and multiple, in our view, are warranted due to an attractive end market and strong historical execution with some elevated risk from a re-accelerating model. Our price target supports an Outperform rating.

Risks to rating and price target

(1) Operates in a market with competition from larger legacy competitors and newer entrants that could lead to potential pricing pressure. (2) Failure to retain existing customers could be a detriment to growth. (3) Needs strong execution to capitalize on R&D and S&M investments. (4) The risk of extended deal cycles as a result of expanded product offerings. (5) COVID-19 could impact company operations or customer demand.

Pubmatic, Inc. (NASDAQ: PUBM)

Matthew Swanson (Analyst)

(612) 313-1237

matthew.swanson@rbccm.com

Rating: Outperform

Closing Price: \$27.05

Price Target: \$47.00

Implied All-in Return: 73.8%

Most recent company note: [link](#)

Investment summary

PubMatic is one of the largest independent sell-side advertising platforms (SSP) offering buyers and sellers of digital advertising a single partner for transacting globally across a variety of channels, formats, and auction types. In 2020, PubMatic generated \$149M in Revenue (+31% Y/Y), driven primarily by growth in the company's faster-growing CTV/OTT, Mobile and Video segments. PubMatic processed 46.9T Ad Impressions in 2020 (+69%) at an average CPM of \$3.6 (-30%). PubMatic has a multi-year track record of generating positive EBITDA and delivered 34% EBITDA margins in 2020.

Valuation

We calculate our base-case price target of \$47 by applying an 8.1x multiple to our CY/23E revenue estimate. Our target multiple is in-line with ad-tech peers at 8.1x CY/23E EV/S, in our view, warranted due to the potential for upside to estimates, better profitability and slightly higher growth in its updated outlook. Our price target supports our Outperform rating.

Risks to rating and price target

(1) Pubmatic has seen both headwinds and tailwinds resulting from the COVID-19 environment, which could impact the advertising industry and the company's performance. (2) Pubmatic is a transactional model; revenue is based on the number of transactions and could lead to more revenue variability based on company specific and macro challenges. (3) Pubmatic is tied to the advertising vertical; any macroeconomic event that impacts the supply or demand of digital advertising could cause an adverse impact on their end markets disproportionately to other software markets. (4) Pubmatic has created an advantage in CTV/OTT as well as mobile and video channels. Failure to manage and defend these emerging growth opportunities could lead to market share losses.

Rapid7 Inc. (NASDAQ: RPD)

Matthew Hedberg (Analyst)

(612) 313-1293

matthew.hedberg@rbccm.com

Rating: Outperform

Closing Price: \$116.25

Price Target: \$138.00

Implied All-in Return: 18.7%

Most recent company note: [link](#)

Investment summary

Rapid7 is a cyber-security vendor with a unique data- and analytics-driven approach to DevSecOps. Its value proposition is to utilize massive amounts of data collected from the network and endpoints to drive automation and productivity to help customers proactively prevent security breaches. ARR growth is the key metric, and management expects it to remain at or above 20% through 2022. **We are confident about the opportunity in the core-VM market**, which is currently over half of the business, with above market growth rates, consistent competitive win rates and minimal pricing pressure while longer-term success in IDR, AppSec and Connect should drive a unique position in the DevSecOps market. **The company has multiple product drivers over multiple years** that should help sustain durable growth and measured operating margin expansion. Currently, base growth is via VM with IDR providing higher levels of growth that longer term should be buoyed by AppSec and Connect. The company is looking for ARR to grow at 20%+ through 2022 with 200–300 bps of annual margin expansion expected with ARR growth in the low- to mid-20% range, 100–200 bps of annual margin expansion with ARR growth in the mid- to high-20% range, and 30%.

Valuation

We calculate our price target of \$138 using a 14x CY/22E EV/S multiple with our increased multiple reflecting our increased sales estimates and recent peer group multiple expansion. The multiple is in line with security peers, which we believe is reasonable with an above-average growth rate but less profitability. Our price target supports an Outperform rating.

Risks to rating and price target

Risks to our price target and rating could include changes in the macro environment including COVID-19 that could continue on longer than expected, moderating IT spending, limited operating history, or should acceptance of the company's products change.

Investment Summaries – Biopharma

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA)

Kennen MacKay (Analyst)
(212) 905-5980
kennen.mackay@rbccm.com

Rating: Outperform
Closing Price: \$50.76
Price Target: \$76.00
Implied All-in Return: 49.7%
Most recent company note: [link](#)

Investment summary

We rate ARNA shares Outperform based on etrasimod's potentially best-in-class clinical-stage profile and the company's cash position after the outlicense of ralinepag, which marks a promising transition away from its prior profile as an obesity play.

Etrasimod presents a compelling opportunity in the ulcerative colitis (UC) market, where a significant unmet need exists for patients who are refractory to or relapsed on biologic therapy. Sphingosine-1-phosphate (S1P) receptor modulators, including ozanimod (CELG), and janus kinase (JAK) inhibitors, including Xeljanz (PFE), are the leading, emergent classes of drugs to fill this unmet need in UC. Based on ph2 data seen thus far, we view etrasimod as, at worst, competitive with other therapies in the post-biologic setting. Should etrasimod establish results in a ph3 trial similar to those seen in ph2 among a heavily pre-treated patient population, we would view this drug's prospects as potentially best-in-class and see it becoming a primary therapy of choice for moderate-to-severe UC patients. **ARNA outlicensed global rights to its other late-stage asset, ralinepag, to United Therapeutics (UTHR) at the end of 2018.** We see this deal validating ARNA's small molecule medicinal chemistry under BD scrutiny from an industry leader, and countering bearish concern that ARNA's potentially blockbuster assets have been passed over amidst BD activity in the space (i.e., JnJ's \$30B Actelion acquisition in the PAH space and CELG's \$7B acquisition of competitive S1P inhibitor ozanimod). The \$800M upfront payment provided ARNA with the financial and operational flexibility to focus on the larger market opportunities for its GI franchise.

Valuation

Our base case DCF-derived valuation is based on the PoS-adjusted NPV of etrasimod sales in ulcerative colitis (75% PoS), Crohn's disease (15% PoS), atopic dermatitis (10% PoS), and ralinepag royalties in pulmonary arterial hypertension (75% PoS). Under our assumptions, etrasimod contributes \$63/sh, ralinepag royalties contribute \$2/sh, and cash contributes \$11/sh to our \$76 YE:21 price target. We utilize an 8.5% discount rate, in line with other clinical-stage biotechnology companies. These assumptions support our \$76 price target and Outperform rating.

Risks to rating and price target

We stay aware of the risks associated with etrasimod, which include clinical risk, regulatory risk, and commercial risk. The clinical risk centers around etrasimod's two pivotal UC ph3 readouts expected in 1Q:22. We believe the drug needs to show a stronger efficacy profile vs. competitor ozanimod and a favorable safety profile that enables a differentiated label allowing easier manageability. Etrasimod's regulatory risk has been reduced with the approval of BMS' ozanimod, which belongs to the same S1P drug class, while a NDA submission and manufacturing site visit during the pandemic are still the existing risk factors for a timely final approval. Etrasimod's commercial risk mainly relates to ARNA's ability to execute as a stand-alone biotech company to compete with large pharmaceutical companies and other classes of drugs besides ozanimod like JAK inhibitors.

Global Blood Therapeutics, Inc. (NASDAQ: GBT)

Gregory Renza (Analyst)

(212) 858-7065

gregory.renza@rbc.com

Rating: Outperform

Closing Price: \$28.28

Price Target: \$66.00

Implied All-in Return: 133.4%

Most recent company note: [link](#)

Investment summary

We believe Oxbryta, GBT's first-in-class FDA-approved sickle hemoglobin (HbS) polymerization inhibitor, could address the unmet need of sickle cell disease patients without suitable donors for hematopoietic stem cell transplant. We see Oxbryta's potential to become SOC in SCD from favorable long-term efficacy and safety profile and enthusiasm from HCP, coupled with the potential label expansion into pediatric population aged 4+ and in ex-U.S. regions which could also contribute to share appreciation potential. **We expect to see continued market uptake for the Oxbryta launch, while COVID-19 headwinds are real though temporary.** We continue to see the value of Oxbryta in the long term with peak global sales potential of over \$1.7B in age 12+ in the late 2020s with potential additional sales opportunities from label expansion – though we look to the progress on the clinical and regulatory fronts, as well as receptivity of the company's marketing efforts. **Development efforts of P-selectin antibody inclacumab, next-gen HbS polymerization inhibitor GBT021601 and HbF-inducing gene therapy could contribute to upside potential.** The pipeline assets complement Oxbryta in SCD management, add to the revenue of GBT, as well as contribute to the long-term life-cycle management and pipeline diversity of the company, in our view. **Key positives:** (1) Valid scientific and biological rationale demonstrated from favorable efficacy and safety profiles; (2) Strong enthusiasm from physicians around the clinical profile of Oxbryta with potential as SOC; (3) Continued marketing efforts could drive increased market uptake despite temporary COVID-19 headwinds; (4) Pipeline assets could generate additional revenue comp; (5) Experienced management team and investor base with proven track record in drug development.

Valuation

Our base case is driven by a 90% probability of success for Oxbryta in age 12+ with ~\$1.4B global peak sales potential and 60% probability of success for Oxbryta in age 4-11 with ~\$300M global peak sales potential. With a 5% probability of success, inclacumab could generate over \$300M WW out-year revenues. Our \$66 price target is based on a blend of DCF (using 10% discount rate and 0.5% terminal growth rate) and probability-adjusted multiples (20x on 2025E adjusted EPS with a 10% discount) analyses. Our valuation supports an Outperform rating.

Risks to rating and price target

(1) Post-marketing studies fail to demonstrate long-term efficacy and safety; (2) Low market penetration despite efforts to drive market uptake; (3) Increasing competition from chronic or gene therapies for SCD in development; (4) Early pipeline programs pose uncertainty to clinical success and longer-term platform potential; (5) COVID-19 disruption on regulatory, clinical, and commercial fronts.

Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)

Brian Abrahams (Analyst)
(212) 858-7066
brian.abrahams@rbc.com

Rating: Outperform

Closing Price: \$31.11

Price Target: \$45.00

Implied All-in Return: 44.7%

Most recent company note: [link](#)

Investment summary

Based on unique pharmacology enabling broad activity across a spectrum of brain receptors, a clean safety profile, and positive physician feedback that supports use in schizophrenia, we believe Caplyta could be a highly differentiated schizophrenia treatment. Following approval in schizophrenia and with what we view as a clean and potentially differentiated label—particularly regarding the safety profile—we model >\$600M in out-year WW revenues for Caplyta in schizophrenia. With lumateperone's commercial potential in schizophrenia and positive data in bipolar depression, we believe shares are undervalued and have upside potential into commercial updates in schizophrenia, regulatory updates in bipolar depression, and further '214 PD readouts. **Key positives:** (1) Recent approval in schizophrenia, following mixed ph.III efficacy data; (2) Lumateperone may be uniquely useful against the negative and cognitive schizophrenia symptoms, due to distinct pharmacological properties that enable activity across a number of brain receptors; (3) positive recent BPD data in adjunctive setting; (4) schizophrenia approval may reduce risk to path forward in BPD, given ability to file sNDA; and (5) blockbuster potential of a drug with broad applicability across psychiatric conditions.

Valuation

Our \$45 price target blends DCF (using a 10% discount rate and 1.5% terminal growth rate) and probability-adjusted multiples (30x on 2024E adjusted EPS with a 10% discount) analyses. Our price target supports an Outperform rating.

Risks to rating and price target

(1) If Caplyta fails to differentiate itself in an increasingly crowded generics space, opportunity in schizophrenia may be more limited; (2) ITCI needs to continue to build commercial infrastructure prior to launch, which carries inherent risk for a smaller company; (3) Failure to receive regulatory approval in BPD may limit commercial opportunity; (4) ITI-214 is relatively early-stage with limited data—clinical failure of this compound would reduce revenue potential post-lumateperone patent expiry; (5) Potential COVID-19 impacts on clinical trial conduct and Caplyta launch.

Sarepta Therapeutics, Inc. (NASDAQ: SRPT)

Brian Abrahams (Analyst)
(212) 858-7066
brian.abrahams@rbc.com

Rating: Outperform
Closing Price: \$78.33
Price Target: \$148.00
Implied All-in Return: 88.9%
Most recent company note: [link](#)

Investment summary

We believe the key value driver for shares going forward will be progress toward the multibillion-dollar opportunity we see for Sarepta's two most advanced muscular dystrophy gene therapy programs. Based on the robust expression, biomarker and safety data for both programs to date—along with highly encouraging functional gains—we believe SRPT could have the best-in-class therapy for both Duchenne and limb girdle muscular dystrophy. Underpinning the significant promise of its gene therapy pipeline are approved drugs (Exondys 51, Vyondys 53, and Amondys 45) addressing a subgroup of DMD patients, and a strong balance sheet bolstered by what we view as a highly validating ex-U.S. microdystrophin DMD gene therapy commercialization deal with Roche. Given Exondys's strong launch, Vyondys's recent approval, positive initial PPMO data, and our increasing optimism around microdystrophin and limb girdle muscular dystrophy gene therapy programs, we believe shares are currently undervalued. **Key positives:** (1) potentially transformative clinical-stage gene therapy programs represent a substantial opportunity; (2) strong U.S. Exondys 51 launch, with quick uptake and high visibility for growth; and (3) regulatory success with Vyondys 53 accelerated approval.

Valuation

Our \$148 price target blends DCF (using a 10.5% discount rate and a 3.0% terminal growth rate) and probability-adjusted multiples (30x on 2025E adjusted EPS discounted at 10.5%) analyses. Our price target supports an Outperform rating.

Risks to rating and price target

(1) Clinical, manufacturing, or regulatory setbacks in DMD or LGMD gene therapy programs; (2) Slower-than-anticipated growth or other commercial setbacks for Exondys 51, Vyondys 53, and Amondys 45; (3) Failure to successfully develop and gain regulatory approval for follow-on exon-skipping drugs, including PPMOs; (4) Poor performance in confirmatory study leading to market removal or increased patient discontinuations; and (5) Sustained and/or escalating negative impacts from COVID-19.

Investment Summaries – Healthcare Technology

OptimizeRx Corp (NASDAQ: OPRX)

Sean Dodge (Analyst)
(615) 372-1322
sean.dodge@rbccm.com

Rating: Outperform
Closing Price: \$64.77
Price Target: \$67.00
Implied All-in Return: 3.4%
Most recent company note: [link](#)

Investment summary

OPRX is a leading digital communications solutions platform helping life sciences companies to optimize the growing proportion of marketing spend being directed through digital channels. We expect revenue to grow at a 30%+ CAGR over the next 3+ years, driven by a combination of: (1) strong macro tailwinds—an increasing proportion of the \$20B+ spent annually by pharma companies on S&M is being diverted to digital channels; (2) deepening integration of OPRX into its clients' commercial planning processes; (3) ongoing transition to more Enterprise-type engagements, which both acts as a multiplier on revenue and increases client "stickiness"; (4) cross-selling into its existing client base—adding both new brands and indications; and (5) signing new clients. Further, a majority of OPRX's revenue is driven by solutions that use a combination of algorithms and EHR integrations to intelligently deliver relevant content to docs at the point of care, meaning that they are very scalable. Consequently, we expect the incremental margins on revenue growth to be very high (i.e., 50%+), helping to drive EBITDA margins to 30%+ at maturity.

Valuation

Our \$67 price target is based on a trading comparable analysis of OPRX vs. its HCIT and Technology peers. OPRX exhibits all of the "tech"-like attributes we look for in digital health companies: big/under-penetrated TAM, steep revenue growth trajectory, and a scalable model. Its Healthcare peers currently trade at an average of 6.5x '22E revenue while its Technology peers trade closer to 16x (ranging from 5.5x to 32x). OPRX shares currently trade at 13x our '22 revenue estimate and our \$67 price target is based on a 14x multiple—as the company's mix of the more recurring/sticky Enterprise deals continues to grow, we expect it to trade closer to the Tech group. Our valuation work and price target support our Outperform rating.

Risks to rating and price target

Risks to our rating and price target include the loss of provider network exclusivity, direct and indirect competition for pharmaceutical marketing dollars, significant customer concentration, and client brands losing exclusivity/facing competition from generics.

Tabula Rasa HealthCare Inc. (NASDAQ: TRHC)

Sean Dodge (Analyst)

(615) 372-1322

sean.dodge@rbccm.com

Rating: Outperform

Closing Price: \$31.26

Price Target: \$70.00

Implied All-in Return: 123.9%

Most recent company note: [link](#)

Investment summary

Tabula Rasa's (TRHC) solutions aim to reduce the financial and medical burdens associated with adverse drug events, which are costly to treat and, worse, are now a leading cause of death. TRHC is a leader in the PACE market, which consists primarily of elderly patients taking 5+ medications per week (i.e., at high risk for ADEs). Our confidence that TRHC can continue to grow 20%+ in this market is based on: (1) the extent to which it has established itself as a trusted partner—90% of existing PACE orgs use a TRHC solution; (2) strengthening regulatory support for the program—namely the intro of 2.0; and (3) the significant white space that remains for cross-selling alone—fully penetrating just existing PACE clients would nearly double its current revenue base. Beyond PACE, TRHC is building solutions to push further into the payer and pharmacy markets. With its unique combination of science and engagement capabilities (via its call centers and growing footprint of pharmacies), TRHC believes it is well positioned to help these “payviders” and pharmacists save money and develop new lines of revenue by improving the health of their patients. Although the pandemic is causing some near-term challenges, we believe it will ultimately be a net tailwind and TRHC will return to its pre-COVID organic revenue growth rate of 20%+.

Valuation

Our \$70 price target is based on the blended 5x EV/'22E sales multiple we derive from our sum-of-the-parts analysis. Our SOP values the CareVention medication fulfillment business at 2.5x NTM sales and the rest of TRHC's software/engagement capabilities at 7.5x—the latter representing a slight discount to similarly growing and profitable digital health peers given TRHC's recent execution hiccups. Our valuation work and price target support our Outperform rating.

Risks to rating and price target

Risks to our Outperform rating and price target include dependence on government programs, customer concentration, competition, prolonged impact from the COVID-19 pandemic and reliance on a single drug vendor for fulfillment services.

Investment Summaries – Energy

Matador Resources Company (NYSE: MTDR)

Scott Hanold (Analyst)
(512) 708-6354
scott.hanold@rbccm.com

Rating: Outperform
Closing Price: \$27.08
Price Target: \$40.00
Implied All-in Return: 48.1%
Most recent company note: [link](#)

Investment summary

We believe MTDR shares will outperform peers over the next 12 months. Management has built a large Permian Basin position of 125,000 net acres that contains over a decade of drilling locations. Additionally, the company is advantaged with in-basin Permian gathering, transportation, and processing through a 51% ownership stake in San Mateo Midstream, LLC joint venture. **MTDR is the operator on the majority of its core acreage development** and the company has a track record of exceeding investors' operational and financial expectations and we believe that trend should continue. **Management and insider ownership is high relative to peers.** The management team insider ownership of MTDR is nearly 6.5%, which is more than 3x its peers. **Current ESG efforts include reducing air emissions and water usage,** increasing corporate diversity, BoD independence, and high insider ownership. **MTDR is differentiated from its SMid-cap peers** by the high concentration in the respective core development areas, including the federal acreage in the Stateline area. **At our mid-cycle oil price scenario (\$55/bbl, WTI),** economic growth rates could average 5-10% over a several year period, above the SMid cap peer group. **Ownership in San Mateo Midstream** is accretive for the upstream business through its low-cost structure and access to key sales points. Third-party revenues provide another avenue for cash flow. San Mateo should generate FCF moving forward. **MTDR holds over 11,000 net royalty acres** (including 6,900 net mineral acres) in the Permian that could provide value in monetization or a strategic development.

Valuation

Our \$40/share price target is derived from a combination of evaluating forward EBITDA multiples, relative FCF levels, and our Net Asset Value (NAV). Our price target, NAV upside opportunity, and cash flow outlook support our Outperform rating. Our target reflects: (1) a price target that is a premium to our \$33/share NAV, a premium to the 5-10% SMid cap peer average premium due to relative operational execution, acreage quality, and the midstream advantage. Our NAV is a risked assessment of 3P reserves using the long-term RBC commodity price outlook of \$55/bbl (WTI), \$60/bbl (Brent), and \$2.65/Mcf (HH); (2) a 7.0 multiple on our 2021 EBITDA estimate, a premium to the 5.5x peer average, warranted given the depth of its inventory, midstream ownership, and higher growth rates.

Risks to rating and price target

(1) Well results and operational execution below expectations would have an adverse effect on the stock performance. (2) Regulatory changes on federal lands could adversely impact MTDR's development opportunities and economics. (3) Weaker-than-expected commodity prices could cause the stock to perform below our expectations and impede achievement of our price target objective.

Sunnova Energy International Inc. (NYSE: NOVA)

Elvira Scotto (Analyst)
(212) 905-5957
elvira.scotto@rbccm.com

Rating: Outperform

Closing Price: \$34.79

Price Target: \$59.00

Implied All-in Return: 69.6%

Most recent company note: [link](#)

Investment summary

NOVA is a leading provider of residential rooftop solar services in the United States. We estimate NOVA has ~4-5% market share of the US residential rooftop solar market, but a higher share of the market's growth. NOVA operates under the dealer model, whereby its dealers originate leads and complete the installation of solar systems. NOVA offers customers leases, PPAs and loans, which NOVA retains on its balance sheet. Rooftop solar penetration in the United States is ~4% according to Wood Mackenzie, providing a significant growth opportunity. The recent extension of the investment tax credit for rooftop solar panels should help drive growth over the next several years.

Valuation

We derive our price target of \$59 for NOVA using a sum-of-the-parts analysis. We view NOVA's value having two components: (1) current net earning assets (which represents the value to equity holders already in NOVA's balance sheet); (2) equity value of future customers, which reflects what we believe is the value to equity holders from NOVA's future growth. We derive equity value of future customers using a discounted cash flow analysis, based on a 5% discount rate, 4% cost of debt, and 9% cost of equity. We forecast growth decelerates from 52% to 5% through 2035, and use a 4% terminal growth rate. Our \$59 price target supports our Outperform rating.

Risks to rating and price target

(1) While the federal government has extended the commercial investment tax credit, potential changes in state regulations could impact the growth of rooftop solar. Specifically, changes to net metering policies could affect the value proposition of rooftop solar relative to traditional utilities given the potential lengthening of a homeowner's payback period as net metering allows homeowners with rooftop solar to sell back power into the grid (thus lowering the homeowner's electricity bill). (2) Rising interest rates increase the cost of debt and consequently the cost of capital, which in turn could drive returns lower. That said, historically utilities have passed on the cost of rising rates to consumers. If that holds true, then NOVA should be able to increase its rates while still maintaining a competitive rate vs utilities. (3) NOVA is dependent on debt and tax equity to finance its growth. If the cost of financing increases or financing is not available at optimal terms, then NOVA's returns could deteriorate. Specifically, NOVA has used low-cost tax equity structures to finance its business and inability to use these structures in the future could slow growth. (4) NOVA's growth potential could stall or returns could decline if its product suppliers were to encounter supply chain issues that either slowed production (shortage of solar modules or batteries) or increased costs. In addition, tariffs on solar modules and inverters have led to lower cost declines than in the past.

Investment Summaries – Financials

Goosehead Insurance Inc. (NASDAQ: GSHD)

Mark Dwelle (Analyst)
(804) 782-4008
mark.dwelle@rbccm.com

Rating: Outperform
Closing Price: \$129.55
Price Target: \$155.00
Implied All-in Return: 19.6%
Most recent company note: [link](#)

Investment summary

Goosehead is an innovative player in the personal lines brokerage industry. Its fully integrated sales and service platform is a sizeable competitive advantage relative to other independent agents and captive agents and gives the company a cost and efficiency edge that is likely to prove sustainable for some time. Equally, its innovative Corporate/Franchise model enables the company to significantly leverage its technology edge and is a coiled economic spring for revenue and earnings growth. We see a long runway of growth ahead and expect that under normalized conditions the company can sustain revenue growth of +30% for the next three to five years with corresponding earnings growth from leverage and platform expansion. Our Outperform rating reflects its attractive high-cash-flow business model and the long-term growth characteristics of the business model. **Technology edge:** The company's IT platform has three main advantages that competitors cannot easily match, in our view: an integrated sales and service platform, proprietary data, and advanced analytics to drive superior lead generation. **Franchise model:** The company's franchise model allows growth with minimal investment. The company earns 20% of commissions on new and 50% on recurring business for providing technology and service support to its franchise agents. **High cash flow and recurring revenue visibility:** About 85–90% of customers renew and a service culture drives high retention. Homeowners insurance is a required purchase and premiums are usually escrowed, which improves retention even during difficult economic conditions. **Direct-to-consumer:** While direct-to-consumer sales comprise only about 18% of personal lines sales, they are a growing proportion and represent a long-term headwind for all types of agents. The company's technology approach is designed to address this potential long-term challenge.

Valuation

Our price target of \$155 is based on 89x our 2023 EPS estimate. Our target multiple considers the company's strong expected growth rates over the next three to five years, rising EBITDA growth as a result of business leverage implicit in the company's franchise model and its capital-light operating model. We view the multiple as consistent with multiples for other high-growth, high-cash-flow companies, but at a premium to traditional broker peers. Our price target and implied return support our Outperform rating.

Risks to rating and price target

The insurance brokerage industry presents a range of unique business risks, many of which could impact our investment rating, the most foreseeable of which include the following: key man risk, information security risk, and regulatory risk in the various states in which the company operates. The company is also exposed to certain economic and recession risks, particularly related to the US housing market and any changes in competition or pricing of industry commissions. A more comprehensive list of potential risk exposures is included in the company's 10-K and other recent filings.

Kinsale Capital Group Inc (NASDAQ: KNSL)

Mark Dwelle (Analyst)
(804) 782-4008
mark.dwelle@rbccm.com

Rating: Outperform
Closing Price: \$175.49
Price Target: \$235.00
Implied All-in Return: 34.2%
Most recent company note: [link](#)

Investment summary

Kinsale is the rare P&C insurer with the ability to achieve strong premium growth while at the same time delivering above-average underwriting margins. The company's technology platform is a key differentiator against all but its largest peers, which positions Kinsale to better serve its distribution partners and in turn drives its opportunity to profitably increase market share within focused customer segments while still maintaining a low expense ratio. Focusing on hard-to-place risks in the E&S market, Kinsale has a long runway available for future growth. We expect the company to continue to achieve strong premium growth near term while generating mid-80s (or better) combined ratios and steady reserving. Management's experience in building specialty insurance organizations is a unique feature that gives us confidence that Kinsale can execute its business strategy. Our Outperform rating is premised on these main points: **A platform for growth:** We believe Kinsale can achieve a normalized double-digit organic growth rate through a continued focus on hard-to-place risk and a willingness to offer terms on risks requiring more extensive underwriting. **Demonstrated underwriting skill:** Management has demonstrated the ability to underwrite profitably with combined ratios in the mid-80s (or better). We expect this will continue over the near term. **Technology supporting a low expense ratio:** Kinsale's expense ratio is several points better than peers, reflecting lower acquisition costs and a technology-aided expense structure. We anticipate this advantage will persist as the company continues to expand its distribution. **The economy and growth:** Kinsale's ability to drive strong premium growth will depend in part on the economy and how it impacts its small business customers. Near term we see the economy as a tailwind.

Valuation

Our \$235 price target is based on approximately 6.8x estimated full-year 2022 book value per share. While this multiple is above many specialty peers, we believe it is supported by a superior combined ratio performance and promising long-term growth potential. Our price target considers Kinsale's operating ROE, premium growth rate and above-average combined ratio, all of which are better than peers. We also consider the company's comparatively shorter operating history. Our price target is consistent with our Outperform rating.

Risks to rating and price target

The main risks to our rating would include industry-wide pricing deterioration, large or unusual catastrophe losses in Kinsale's property business, and adverse development in ongoing business interruption litigation surrounding COVID-19. Like most P&C companies, reserves are always a risk and subject to estimation error. Kinsale also has a significant equity portfolio, and could see book value fluctuate alongside broader equity markets.

Contributing Authors

RBC Capital Markets, LLC

Brian Abrahams (Analyst)	(212) 858-7066	brian.abrahams@rbc.com
Sean Dodge (Analyst)	(615) 372-1322	sean.dodge@rbccm.com
Mark A. Dwelle (Analyst)	(804) 782-4008	mark.dwelle@rbccm.com
Brad Erickson (Analyst)	(503) 830-9488	brad.erickson@rbccm.com
Scott Hanold (Analyst)	(512) 708-6354	scott.hanold@rbccm.com
Matthew Hedberg (Analyst)	(612) 313-1293	matthew.hedberg@rbccm.com
Luca Issi (Analyst)	(212) 266-4089	luca.issi@rbccm.com
Kennen MacKay (Analyst)	(212) 905-5980	kennen.mackay@rbccm.com
Frank G. Morgan (Analyst)	(615) 372-1331	frank.morgan@rbccm.com
Daniel R. Perlin (Analyst)	(410) 625-6130	daniel.perlin@rbccm.com
Gregory Renza (Analyst)	(212) 858-7065	gregory.renza@rbc.com
Elvira Scotto (Analyst)	(212) 905-5957	elvira.scotto@rbccm.com
Matthew Swanson (Analyst)	(612) 313-1237	matthew.swanson@rbccm.com

Required disclosures

Conflicts disclosures

This product constitutes a compendium report (covers six or more subject companies). As such, RBC Capital Markets chooses to provide specific disclosures for the subject companies by reference. To access conflict of interest and other disclosures for the subject companies, clients should refer to <https://www.rbccm.com/GLDisclosure/PublicWeb/DisclosureLookup.aspx?entityId=1>. These disclosures are also available by sending a written request to RBC Capital Markets Research Publishing, P.O. Box 50, 200 Bay Street, Royal Bank Plaza, 29th Floor, South Tower, Toronto, Ontario M5J 2W7 or an email to rbcinsight@rbccm.com.

The analyst(s) responsible for preparing this research report received compensation that is based upon various factors, including total revenues of the member companies of RBC Capital Markets and its affiliates, a portion of which are or have been generated by investment banking activities of the member companies of RBC Capital Markets and its affiliates.

Distribution of ratings

For the purpose of ratings distributions, regulatory rules require member firms to assign ratings to one of three rating categories - Buy, Hold/Neutral, or Sell - regardless of a firm's own rating categories. Although RBC Capital Markets' ratings of Outperform (O), Sector Perform (SP), and Underperform (U) most closely correspond to Buy, Hold/Neutral and Sell, respectively, the meanings are not the same because our ratings are determined on a relative basis.

Distribution of ratings				
RBC Capital Markets, Equity Research				
As of 30-Jun-2021				
Rating	Count	Percent	Investment Banking	
			Serv./Past 12 Mos.	
			Count	Percent
BUY [Outperform]	787	55.70	318	40.41
HOLD [Sector Perform]	575	40.69	173	30.09
SELL [Underperform]	51	3.61	4	7.84

Conflicts policy

RBC Capital Markets Policy for Managing Conflicts of Interest in Relation to Investment Research is available from us on request. To access our current policy, clients should refer to <https://www.rbccm.com/global/file-414164.pdf> or send a request to RBC Capital Markets Research Publishing, P.O. Box 50, 200 Bay Street, Royal Bank Plaza, 29th Floor, South Tower, Toronto, Ontario M5J 2W7. We reserve the right to amend or supplement this policy at any time.

Dissemination of research and short-term trade ideas

RBC Capital Markets endeavors to make all reasonable efforts to provide research simultaneously to all eligible clients, having regard to local time zones in overseas jurisdictions. RBC Capital Markets' equity research is posted to our proprietary website to ensure eligible clients receive coverage initiations and changes in ratings, targets and opinions in a timely manner. Additional distribution may be done by the sales personnel via email, fax, or other electronic means, or regular mail. Clients may also receive our research via third party vendors. RBC Capital Markets also provides eligible clients with access to SPARC on the Firm's proprietary INSIGHT website, via email and via third-party vendors. SPARC contains market color and commentary regarding subject companies on which the Firm currently provides equity research coverage. Research Analysts may, from time to time, include short-term trade ideas in research reports and / or in SPARC. A short-term trade idea offers a short-term view on how a security may trade, based on market and trading events, and the resulting trading opportunity that may be available. A short-term trade idea may differ from the price targets and recommendations in our published research reports reflecting the research analyst's views of the longer-term (one year) prospects of the subject company, as a result of the differing time horizons, methodologies and/or other factors. Thus, it is possible that a subject company's common equity that is considered a long-term 'Sector Perform' or even an 'Underperform' might present a short-term buying opportunity as a result of temporary selling pressure in the market; conversely, a subject company's common equity rated a long-term 'Outperform' could be considered susceptible to a short-term downward price correction. Short-term trade ideas are not ratings, nor are they part of any ratings

system, and the firm generally does not intend, nor undertakes any obligation, to maintain or update short-term trade ideas. Short-term trade ideas may not be suitable for all investors and have not been tailored to individual investor circumstances and objectives, and investors should make their own independent decisions regarding any securities or strategies discussed herein. Please contact your investment advisor or institutional salesperson for more information regarding RBC Capital Markets' research.

For a list of all recommendations on the company that were disseminated during the prior 12-month period, please click on the following link: <https://rbcnew.bluematrix.com/sellside/MAR.action>

The 12 month history of SPARCs can be viewed at <https://www.rbcinsightresearch.com/>.

Analyst certification

All of the views expressed in this report accurately reflect the personal views of the responsible analyst(s) about any and all of the subject securities or issuers. No part of the compensation of the responsible analyst(s) named herein is, or will be, directly or indirectly, related to the specific recommendations or views expressed by the responsible analyst(s) in this report.

Third-party-disclaimers

The Global Industry Classification Standard ("GICS") was developed by and is the exclusive property and a service mark of MSCI Inc. ("MSCI") and Standard & Poor's Financial Services LLC ("S&P") and is licensed for use by RBC. Neither MSCI, S&P, nor any other party involved in making or compiling the GICS or any GICS classifications makes any express or implied warranties or representations with respect to such standard or classification (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability and fitness for a particular purpose with respect to any of such standard or classification. Without limiting any of the foregoing, in no event shall MSCI, S&P, any of their affiliates or any third party involved in making or compiling the GICS or any GICS classifications have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages.

RBC Capital Markets disclaims all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any statements made to the media or via social media that are in turn quoted in this report, or otherwise reproduced graphically for informational purposes.

References herein to "LIBOR", "LIBO Rate", "L" or other LIBOR abbreviations means the London interbank offered rate as administered by ICE Benchmark Administration (or any other person that takes over the administration of such rate).

Disclaimer

RBC Capital Markets is the business name used by certain branches and subsidiaries of the Royal Bank of Canada, including RBC Dominion Securities Inc., RBC Capital Markets, LLC, RBC Europe Limited, RBC Capital Markets (Europe) GmbH, Royal Bank of Canada, Hong Kong Branch and Royal Bank of Canada, Sydney Branch. The information contained in this report has been compiled by RBC Capital Markets from sources believed to be reliable, but no representation or warranty, express or implied, is made by Royal Bank of Canada, RBC Capital Markets, its affiliates or any other person as to its accuracy, completeness or correctness. All opinions and estimates contained in this report constitute RBC Capital Markets' judgement as of the date of this report, are subject to change without notice and are provided in good faith but without legal responsibility. Nothing in this report constitutes legal, accounting or tax advice or individually tailored investment advice. This material is prepared for general circulation to clients and has been prepared without regard to the individual financial circumstances and objectives of persons who receive it. The investments or services contained in this report may not be suitable for you and it is recommended that you consult an independent investment advisor if you are in doubt about the suitability of such investments or services. This report is not an offer to sell or a solicitation of an offer to buy any securities. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. RBC Capital Markets research analyst compensation is based in part on the overall profitability of RBC Capital Markets, which includes profits attributable to investment banking revenues. Every province in Canada, state in the U.S., and most countries throughout the world have their own laws regulating the types of securities and other investment products which may be offered to their residents, as well as the process for doing so. As a result, the securities discussed in this report may not be eligible for sale in some jurisdictions. RBC Capital Markets may be restricted from publishing research reports, from time to time, due to regulatory restrictions and/or internal compliance policies. If this is the case, the latest published research reports available to clients may not reflect recent material changes in the applicable industry and/or applicable subject companies. RBC Capital Markets research reports are current only as of the date set forth on the research reports. This report is not, and under no circumstances should be construed as, a solicitation to act as securities broker or dealer in any jurisdiction by any person or company that is not legally permitted to carry on the business of a securities broker or dealer in that jurisdiction. To the full extent permitted by law neither RBC Capital Markets nor any of its affiliates, nor any other person, accepts any liability whatsoever for any direct, indirect or consequential loss arising from, or in connection with, any use of this report or the information contained herein. No matter contained in this document may be reproduced or copied by any means without the prior written consent of RBC Capital Markets in each instance.

Additional information is available on request.

To U.S. Residents: This publication has been approved by RBC Capital Markets, LLC (member FINRA, NYSE, SIPC), which is a U.S. registered broker-dealer and which accepts responsibility for this report and its dissemination in the United States. Any U.S. recipient of this report that is not a registered broker-dealer or a bank acting in a broker or dealer capacity and that wishes further information regarding, or to effect any transaction in, any of the securities discussed in this report, should contact and place orders with RBC Capital Markets, LLC.

To Canadian Residents: This publication has been approved by RBC Dominion Securities Inc. (member IIROC). Any Canadian recipient of this report that is not a Designated Institution in Ontario, an Accredited Investor in British Columbia or Alberta or a Sophisticated Purchaser in Quebec (or similar permitted purchaser in any other province) and that wishes further information regarding, or to effect any transaction in, any of the securities discussed in this report should contact and place orders with RBC Dominion Securities Inc., which, without in any way limiting the foregoing, accepts responsibility for this report and its dissemination in Canada.

To U.K. Residents: This publication has been approved by RBC Europe Limited ('RBCEL') which is authorized by the Prudential Regulation Authority and regulated by the Financial Conduct Authority ('FCA') and the Prudential Regulation Authority, in connection with its distribution in the United Kingdom. This material is not for general distribution in the United Kingdom to retail clients, as defined under the rules of the FCA. RBCEL accepts responsibility for this report and its dissemination in the United Kingdom.

To EEA Residents: This material is distributed in the EU by either RBCEL on an authorised cross-border basis, or by RBC Capital Markets (Europe) GmbH (RBC EG) which is authorised and regulated in Germany by the Bundesanstalt für Finanzdienstleistungsaufsicht (German Federal Financial Supervisory Authority) (BaFin).

To Persons Receiving This Advice in Australia: This material has been distributed in Australia by Royal Bank of Canada, Sydney Branch (ABN 86 076 940 880, AFSL No. 246521). This material has been prepared for general circulation and does not take into account the objectives, financial situation or needs of any recipient. Accordingly, any recipient should, before acting on this material, consider the appropriateness of this material having regard to their objectives, financial situation and needs. If this material relates to the acquisition or possible acquisition of a particular financial product, a recipient in Australia should obtain any relevant disclosure document prepared in respect of that product and consider that document before making any decision about whether to acquire the product. This research report is not for retail investors as defined in section 761G of the Corporations Act.

To Hong Kong Residents: This publication is distributed in Hong Kong by Royal Bank of Canada, Hong Kong Branch, which is regulated by the Hong Kong Monetary Authority and the Securities and Futures Commission (SFC) in Hong Kong, RBC Investment Services (Asia) Limited and RBC Global Asset Management (Asia) Limited, both entities are regulated by the SFC. This material is not for general distribution in Hong Kong to persons who are not professional investors (as defined in the Securities and Futures Ordinance of Hong Kong (Cap. 571) and any rules made thereunder.

To Singapore Residents: This publication is distributed in Singapore by the Royal Bank of Canada, Singapore Branch, a registered entity licensed by the Monetary Authority of Singapore. This material has been prepared for general circulation and does not take into account the objectives, financial situation, or needs of any recipient. You are advised to seek independent advice from a financial adviser before purchasing any product. If you do not obtain independent advice, you should consider whether the product is suitable for you. Past performance is not indicative of future performance. If you have any questions related to this publication, please contact the Royal Bank of Canada, Singapore Branch. Royal Bank of Canada, Singapore Branch accepts responsibility for this report and its dissemination in Singapore.

To Japanese Residents: Unless otherwise exempted by Japanese law, this publication is distributed in Japan by or through RBC Capital Markets (Japan) Ltd. which is a Financial Instruments Firm registered with the Kanto Local Financial Bureau (Registered number 203) and a member of the Japan Securities Dealers Association ("JSDA") and the Financial Futures Association of Japan ("FFAJ").

® Registered trademark of Royal Bank of Canada. RBC Capital Markets is a trademark of Royal Bank of Canada. Used under license.

Copyright © RBC Capital Markets, LLC 2021 - Member SIPC

Copyright © RBC Dominion Securities Inc. 2021 - Member Canadian Investor Protection Fund

Copyright © RBC Europe Limited 2021

Copyright © Royal Bank of Canada 2021

All rights reserved